Angiomyolipoma: Clinical Trials

1 trial for Angiomyolipoma, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

1 completed. 1 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 31Completed 1

Follow Angiomyolipoma: new trials by email Literature Review of Angiomyolipoma trials Research Report on Angiomyolipoma

Trials (filtered) newest first · largest first

All 1 trial

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Efficacy and Safety of RAD001 in Patients Aged 18 and Over With Angiomyolipoma Associated With Either Tuberous Sclerosis Complex (TSC) or Sporadic Lymphangioleiomyomatosis (LAM)
Everolimus (RAD001), Everolimus Placebo - Tuberous Sclerosis Complex (TSC), Lymphangioleiomyomatosis (LAM)
Phase 3CompletedNovartis Pharmaceuticals1182009-04-012017-02-17

Narrower conditions

Astrocytoma (1)  ·  Hereditary Sensory and Autonomic Neuropathies (1)  ·  Lymphangioleiomyomatosis (1)  ·  Seizures (1)  ·  Tuberous Sclerosis (1)  ·  Tuberous Sclerosis 2 (1)

Broader conditions

Congenital Abnormalities (1)  ·  Congenital, Hereditary, and Neonatal Diseases and Abnormalities (1)  ·  Genetic Diseases, Inborn (1)  ·  Glioma (1)  ·  Hamartoma (1)  ·  Hemic and Lymphatic Diseases (1)  ·  Heredodegenerative Disorders, Nervous System (1)  ·  Immune System Diseases (1)  ·  Immunoproliferative Disorders (1)  ·  Lymphangiomyoma (1)  ·  Lymphatic Diseases (1)  ·  Lymphoproliferative Disorders (1)  ·  Malformations of Cortical Development (1)  ·  Malformations of Cortical Development, Group I (1)  ·  Neoplasm, Lymphatic Tissue (1)

Interventions

Everolimus (1)

Sponsors

Novartis Pharmaceuticals (1)

Countries

Canada (1)  ·  France (1)  ·  Germany (1)  ·  Italy (1)  ·  Japan (1)  ·  Netherlands (1)  ·  Poland (1)  ·  Russia (1)  ·  Spain (1)  ·  United Kingdom (1)  ·  United States (1)

Results publications

PMID 26156073, PMID 29023494, PMID 30053159, PMID 30192751

NIH funding

2008 (1)